Biotech | February 13, 2021
Biocon Biologics and Viatris receive European Commission approval for Kixelle, Biosimilar Insulin Aspart
The centralized marketing authorization granted by the EC is valid in all EU Member
The centralized marketing authorization granted by the EC is valid in all EU Member
The partnership is a significant step in delivering advanced cancer therapies to patients.
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
Veteran quality professional with over 20 years of industry experience to lead quality operations at Unit-4 API manufacturing facility
Amitabh Dube and Sheetal Arora named Co-Chairmen for the forthcoming term
Multi-target licensing agreement combines Stipple Bio’s epitope discovery platform with Lonza’s ADC technologies to develop targeted cancer treatments
Dr. Rishi brings more than 15 years of experience in bioprocess development, microbial fermentation, technology transfer, and biotechnology operations
Expands manufacturing push & locks in major growth deals
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
